How do the results of LIBRETTO-432 shape the potential role of adjuvant selpercatinib in patients with early-stage RET fusion-positive NSCLC?

The results of LIBRETTO-432 provide strong evidence to consider selpercatinib for patients with stage II-IIIA RET fusion-positive NSCLC, with a highly significant HR of 0.172 (0.058-0.59) for this cohort. When thinking about stage IB (tumors 3- 4 cm, T2b), most of these patients were not included in...

LIBRETTO-432 is the 3rd RCT to provide evidence supporting the role of adjuvant targeted therapy in oncogenically driven NSCLC. Given the low incidence of RET translocation, this study defined definitive therapy for stage IB-IIIA disease as either surgery or radiotherapy, with primary analysis of EF...